Appendix Table A1. Soluble VEGFR2 concentration between responder and non responders in terms of letter gain within diabetic retinopathy phenotypes different diabetic retinopathy phenotypes.

	> 15 Letter gain (A) Mean (95% of CI)	> 10 Letter gain (B) Mean (95% of CI)	> 5 Letter gain (C) Mean (95% of CI)	No letter gain (D) Mean (95% of CI)	P_{ANOVA}	P_{Tukeys}	
Focal DME_MNPDR	59.99 (33.84 – 86.14)	60.14 (30.68 – 89.60)	61.57 (37.67 – 85.46)	60.20 (46.49 – 73.90)	.90	-	
Focal DME_SNPDR	114.70 (-228.8 – 458.1)	101.10 (73.63 – 128.5)	-	39.26 (22.06 – 56.46)	**.001**	A vs. B A vs. D B vs. D	ns **<.001** **<.001**
Diffuse DME_SNPDR	-	62.82 (50.39 – 75.25)	44.33 (-94.55 – 183.2)	54.09 (31.65 – 76.53)	.30	-	
Diffuse DME_PDR	-	66.51 (44.02 – 89.06)	39.38 (16.45 -62.31)	32.72 (20.44 – 45.00)	**.04**	B vs. C B vs. D C vs. D	ns **<.05** ns

Bold values are significant; CI = confidence interval; DME_MNPDR = diabetic macular edema with mild to moderate non-proliferative diabetic retinopathy; DME_SNPDR = diabetic macular edema with severe non-proliferative diabetic retinopathy; DME_PDR = diabetic macular edema with proliferative diabetic retinopathy.